Biohit Oyj Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Biohit Oyj hat ein Gesamteigenkapital von €10.8M und eine Gesamtverschuldung von €0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen €14.2M bzw. €3.4M.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

€0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	€5.00m
Eigenkapital	€10.80m
Gesamtverbindlichkeiten	€3.40m
Gesamtvermögen	€14.20m

Jüngste Berichte zur Finanzlage

Recent updates

Biohit Oyj's (HEL:BIOBV) Solid Profits Have Weak Fundamentals

Feb 22

Biohit Oyj Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 17

Companies Like Biohit Oyj (HEL:BIOBV) Are In A Position To Invest In Growth

Aug 04

Companies Like Biohit Oyj (HEL:BIOBV) Are In A Position To Invest In Growth

Feb 09

Biohit Oyj (HEL:BIOBV) Is In A Strong Position To Grow Its Business

Aug 11

Biohit Oyj (HEL:BIOBV) Is In A Strong Position To Grow Its Business

Apr 13

We Think Biohit Oyj (HEL:BIOBV) Can Afford To Drive Business Growth

Dec 28

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: BIOBVDie kurzfristigen Aktiva des Unternehmens (€11.8M) übersteigen seine kurzfristigen Passiva (€3.1M).

Langfristige Verbindlichkeiten: BIOBVDie kurzfristigen Vermögenswerte des Unternehmens (€11.8M) übersteigen seine langfristigen Verbindlichkeiten (€435.0K).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: BIOBV ist schuldenfrei.

Schulden abbauen: BIOBV hatte vor 5 Jahren keine Schulden.

Schuldendeckung: BIOBV hat keine Schulden und muss daher nicht durch den operativer Cashflow gedeckt werden.

Zinsdeckung: BIOBV hat keine Schulden, daher ist die Deckung der Zinszahlungen kein Problem.

Biohit Oyj Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Companies Like Biohit Oyj (HEL:BIOBV) Are In A Position To Invest In Growth

Companies Like Biohit Oyj (HEL:BIOBV) Are In A Position To Invest In Growth

Biohit Oyj (HEL:BIOBV) Is In A Strong Position To Grow Its Business

Biohit Oyj (HEL:BIOBV) Is In A Strong Position To Grow Its Business

We Think Biohit Oyj (HEL:BIOBV) Can Afford To Drive Business Growth

Recent updates

First half 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 17% to €2.70

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Biohit Oyj's (HEL:BIOBV) Solid Profits Have Weak Fundamentals

Consensus EPS estimates increase by 18%

Biohit Oyj Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Full year 2023 earnings: Revenues exceed analyst expectations

Biohit Oyj to Report First Half, 2024 Results on Aug 07, 2024

Biohit Oyj Announces Changes in the Management Group

New major risk - Earnings quality

First half 2023 earnings: EPS and revenues exceed analyst expectations

Biohit Revises Earnings Guidance for 2023

Biohit Oyj Approves Election of Vesa Silaskivi as Members of Board of Directors

Full year 2022 earnings released: EPS: €0.04 (vs €0.10 loss in FY 2021)

Investor sentiment deteriorates as stock falls 19%

Biohit Oyj Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released

Biohit Oyj Announces Executive Changes

Biohit Oyj to Report Fiscal Year 2022 Final Results on Mar 22, 2023

No independent directors

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Biohit Oyj Appoints Jussi Sorvo as Chief Financial Officer, Effective on September 7, 2022

Biohit Oyj Announces Executive Changes

Biohit Oyj Appoints Panu Hendolin as Member of the Management Team

First half 2022 earnings released: EPS: €0.06 (vs €0.073 loss in 1H 2021)

Biohit Oyj Revises Earnings Guidance for the Year 2022

Companies Like Biohit Oyj (HEL:BIOBV) Are In A Position To Invest In Growth

Biohit Oyj Appoints Lea Paloheimo as the Chairman of the Board of Directors

Biohit Oyj Elects Kalle Härkönen as Board of Director

Less than half of directors are independent

Full year 2021 earnings: Revenues in line with analyst expectations

Biohit Oyj Provides Earnings Guidance for the Year 2022

Companies Like Biohit Oyj (HEL:BIOBV) Are In A Position To Invest In Growth

Biohit Oyj Specifies Financial Guidance for 2021

Biohit Oyj Announces Recent Clinical Validation Study Confirms the Accuracy of the New-Generation GastroPanel Test in Diagnosis of Atrophic Gastritis and Helicobacter Pylori Infection

First half 2021 earnings released: €0.073 loss per share (vs €0.15 loss in 1H 2020)

Biohit Oyj (HEL:BIOBV) Is In A Strong Position To Grow Its Business

President & CEO Semi Korpela has left the company

Biohit Oyj (HEL:BIOBV) Is In A Strong Position To Grow Its Business

Full year 2020 earnings released: €0.22 loss per share (vs €0.094 loss in FY 2019)

Full year 2020 earnings released: €0.22 loss per share (vs €0.094 loss in FY 2019)

We Think Biohit Oyj (HEL:BIOBV) Can Afford To Drive Business Growth

New 90-day high: €2.26

Biohit Oyj to Report First Half, 2021 Results on Aug 11, 2021

Biohit Oyj to Report Fiscal Year 2020 Results on Feb 17, 2021

New 90-day low: €1.99

New 90-day low: €2.00

Biohit Oyj Elects Osmo Suovaniemi as the Chairman of the Board of Directors

New 90-day low - €2.14

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen